Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions

Chu, Sherman; Michelle, Lauren; Ekelem, Chloe; Sung, Ching-Hwa; Rojek, Nathan W.; Mesinkovska, Natasha Atanaskova

doi:10.1007/s00403-020-02152-4

Cited by 36 publications

(52 citation statements)

References 180 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…56 Isotretinoin has shown discordant results in retrospective cohort studies and case series. 78 Better responses are reported in mild disease and with low doses (<1 mg/kg/d). Isotretinoin should be considered as a second-or third-line therapy or in patients with severe concomitant acne.…”

Section: Topical Treatmentmentioning

confidence: 99%

New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch

Agut-Busquet

Vilarrasa

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by the presence of painful nodules, abscesses, chronically draining fistulas, and scarring in apocrine gland-bearing areas of the body. The exact pathogenesis of HS is not yet well understood, but there is a consensus in considering HS a multifactorial disease with a genetic predisposition, an inflammatory dysregulation, and an influence of environmental modifying factors. Therapeutic approach of HS is challenging due to the wide clinical manifestations of the disease and the complex pathogenesis. This review describes evidence for effectiveness of current and emerging HS therapies. Topical therapy, systemic treatments, biological agents, surgery, and light therapy have been used for HS with variable results. Adalimumab is the only US Food and Drug Administration (FDA) approved biologic agent for moderate-to-severe HS, but new therapeutic options are being studied, targeting different specific cytokines involved in HS pathogenesis. Comparing treatment outcomes between therapies is difficult due to the lack of randomized controlled trials. Treatment strategy should be selected in concordance to disease severity and requires combination of treatments in most cases.

show abstract

Section: Topical Treatmentmentioning

confidence: 99%

New perspectives on the treatment of hidradenitis suppurativa

Amat-Samaranch

Agut-Busquet

Vilarrasa

et al. 2021

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

show abstract

“…[24] Oral monotherapy in 0.5-2mg/kg/day dose showed lesion clearance for two to three months, whereas combination therapy in 0.5-1.5mg/ kg/day showed the same results for three to four months. [25] It reduces the secretion of Sebum and Sebaceous gland and affects the oil skin status. [5][13] [14] In a study carried out by Uma Shankar Agarwal et al, the efficacy and tolerability of various regimens of oral isotretinoin were compared.…”

Section: Therapeutic Effects Of Isotretinoinmentioning

confidence: 99%

13-cis-Retinoic Acid: It’s Therapeutic Implications and Adverse Effects

Panda¹,

Mohammad²,

Dikshit³

2021

JSCRR

View full text Add to dashboard Cite

Isotretinoin (13-cis-retinoic acid) is a second-generation synthetic retinoic acid analog beneficial for the treatment of recalcitrant nodulocystic acne. The 13-cis-retinoic acid is also used to treat oral leukoplakia and has shown mixed results in cancer therapy. It is a much safer drug but can cause severe side effects like teratogenicity, dryness of the skin (including eyes, tongue, mouth, and nasal mucosa), rashes on the face and body, itching, increased photosensitivity, bleeding from the nose (epistaxis), lip inflammation (cheilitis), bleeding & inflammation of gums (gingivitis), and depression & suicidal ideation in patients. It is a schedule H drug and is contraindicated in pregnant women. This review article gives a complete understanding of the pharmacology of Isotretinoin along with the completed clinical trials and research on Isotretinoin for treating other diseases apart from acne and oral leukoplakia. The article also deals in measures to prevent the adverse effects related to 13-cis-retinoic acid.

show abstract

“…Importantly, though, isotretinoin has shown efficacy in the treatment of sebaceous neoplasms associated with MTS, in addition to its well-documented effect on preventing KAs. 2 Herein, we review the literature on the use of isotretinoin in MTS and suggest that isotretinoin chemoprophylaxis may represent a novel therapeutic paradigm in MTS.…”

mentioning

confidence: 99%

“…Off-label uses include nonmelanoma skin cancers, rosacea, condyloma accuminata, and hidradenitis suppurativa. 2 As isotretinoin exhibits potent activity in inducing sebocyte apoptosis and thus represents an ideal therapeutic agent for the sebaceous neoplasms in MTS. Several reports have described not only the regression of cutaneous tumors that had previously required surgical excision, but also prevention of new tumors with isotretinoin.…”

mentioning

confidence: 99%

Isotretinoin as chemoprophylaxis for cutaneous malignancies in Muir‐Torre syndrome: A novel concept

Joshi

Farr

Lewis

2022

Dermatologic Therapy

View full text Add to dashboard Cite

Muir-Torre syndrome (MTS) is an autosomal dominant cancer syndrome that is a phenotypic variant of hereditary nonpolyposis colorectal carcinoma (HNPCC), or Lynch syndrome. MTS is characterized by sebaceous neoplasms and HNPCC-associated malignancies such as colorectal, endometrial, and urothelial carcinomas. The Amsterdam criteria require the presence of at least one sebaceous adenoma, sebaceous epithelioma, sebaceous carcinoma, or keratoacanthoma (KA) with sebaceous differentiation in addition to a HNPCCassociated visceral malignancy. Multiple KAs and a visceral malignancy together with a family history of MTS are also diagnostic. MTS is precipitated by pathogenic variants of DNA mismatch repair genes such

show abstract

Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions

Cited by 36 publications

References 180 publications

New perspectives on the treatment of hidradenitis suppurativa

New perspectives on the treatment of hidradenitis suppurativa

13-cis-Retinoic Acid: It’s Therapeutic Implications and Adverse Effects

Isotretinoin as chemoprophylaxis for cutaneous malignancies in Muir‐Torre syndrome: A novel concept

Contact Info

Product

Resources

About